Bruno Paiva, PhD, from the University of Navarra, Pamplona, Spain discusses open questions in the assessment of response in multiple myeloma (MM). According to Dr Paiva, we should see overall response rates of around 70-80% in a relapsed/refractory setting and complete remission (CR) rates of around 20-30%. In future, a deep response, including minimal residual disease (MRD) negativity, may be a goal for fit relapsed/refractory patients. Other areas that require research are biomarkers and ultra chemotherapy-resistant MRD cells.
Recorded at the 2016 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.